Literature DB >> 11738730

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications.

M R Hilleman1.   

Abstract

Measles is one of the most important diseases of mankind, which is so highly contagious and evokes such persistent immunity that the virus cannot be sustained in a population of less than about 500,000 persons. The first of the licensed live virus vaccines against measles was developed empirically and was approved in 1963. It provides high level and lasting immunity and is a paradigm for solving major medical problems without really understanding them. In spite of means for control by prophylactic immunization, research on measles infection continues to be part of the effort to understand the pathogenesis of many different viruses, which may have important similarities and differences and provide important insights. Measles, usually, is spontaneously reversible and is a prime model for understanding virus-induced immunodeficiency disease (AIDS) which is rarely reversible. Much has been learned of basic immunology and vaccinology in measles through observation of the inappropriate use of vaccines of appropriate composition, and through inappropriate host response to measles vaccines of inappropriate composition. This review provides a current overview of selected highlights of measles, the virus, its immunopathogenesis, and its control by use of live virus vaccine which may lead to elimination of the disease and eventually to eradication of the virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738730     DOI: 10.1016/s0264-410x(01)00384-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

Review 1.  Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.

Authors:  Maurice R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  Multicenter Safety and Immunogenicity Trial of an Attenuated Measles Vaccine for NHP.

Authors:  Joann L Yee; Michael B McChesney; Kari L Christe
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

Review 3.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

4.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Authors:  Anna H Malczyk; Alexandra Kupke; Steffen Prüfer; Vivian A Scheuplein; Stefan Hutzler; Dorothea Kreuz; Tim Beissert; Stefanie Bauer; Stefanie Hubich-Rau; Christiane Tondera; Hosam Shams Eldin; Jörg Schmidt; Júlia Vergara-Alert; Yasemin Süzer; Janna Seifried; Kay-Martin Hanschmann; Ulrich Kalinke; Susanne Herold; Ugur Sahin; Klaus Cichutek; Zoe Waibler; Markus Eickmann; Stephan Becker; Michael D Mühlebach
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

5.  Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity.

Authors:  Laura K White; Jeong-Joong Yoon; Jin K Lee; Aiming Sun; Yuhong Du; Haian Fu; James P Snyder; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

6.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

7.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

9.  High-throughput screening-based identification of paramyxovirus inhibitors.

Authors:  Jeong-Joong Yoon; Dhruv Chawla; Tanja Paal; Maina Ndungu; Yuhong Du; Serdar Kurtkaya; Aiming Sun; James P Snyder; Richard K Plemper
Journal:  J Biomol Screen       Date:  2008-07-14

10.  A target site for template-based design of measles virus entry inhibitors.

Authors:  Richard K Plemper; Karl J Erlandson; Ami S Lakdawala; Aiming Sun; Andrew Prussia; Jutatip Boonsombat; Esin Aki-Sener; Ismail Yalcin; Ilkay Yildiz; Ozlem Temiz-Arpaci; Betul Tekiner; Dennis C Liotta; James P Snyder; Richard W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.